Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15615376 | 0.96 | BRAF (0.70) | BRAFEIF2AK3 | |
| SCHEMBL13625133 | 0.89 | BRAF (0.70) | BRAFEIF2AK3 | |
| SCHEMBL13625132 | 0.87 | BRAF (0.67) | BRAFEIF2AK3 | |
| SCHEMBL2193377 | 0.87 | BRAF (0.77) | BRAF | |
| SCHEMBL30686871 | 0.86 | BRAF (0.70) | BRAFEIF2AK3 | |
| SCHEMBL12350030 | 0.86 | BRAF (0.70) | BRAFEIF2AK3 | |
| SCHEMBL2195395 | 0.85 | BRAF (1.00) | BRAFEIF2AK3 | |
| SCHEMBL2193266 | 0.85 | BRAF (0.77) | BRAFEIF2AK3 | |
| SCHEMBL2193382 | 0.85 | BRAF (0.77) | BRAFEIF2AK3 | |
| SCHEMBL2191913 | 0.84 | BRAF (0.76) | BRAFEIF2AK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| EP-3106462-A1 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | Novartis AG (CH) | 2016-12-21 | — | — | EP | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2016-03-10 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-9233956-B2 | Benzene sulfonamide thiazole and oxazole compounds | NOVARTIS AG (CH) | 2016-01-12 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994185-B2 | Benzene sulfonamide thiazole and oxazole compounds | Glaxo Smith Kline LLC (US) | 2011-08-09 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | NOVARTIS AG (CH) | 2011-07-14 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | NOVARTIS AG (CH) | 2009-12-03 | — | — | US | disclosed |
| WO-2009137391-A2 | BENZENE SULFONAMIDE THIAZOLE AND OXAZOLE COMPOUNDS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172215-A1 | Benzene Sulfonamide Thiazole And Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EIF2AK3 2901/4885 |
| US-20170073341-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EIF2AK3 2901/4885 |
| US-20160068523-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EIF2AK3 2901/4885 |
| US-20090298815-A1 | Benzene Sulfonamide Thiazole and Oxazole Compounds | STS, TST, TPST2 | BRAF 776/4885EIF2AK3 2901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.